Overexpression of Transforming Acidic Coiled Coil‑Containing Protein 3 Reflects Malignant Characteristics and Poor Prognosis of Glioma

Abstract

Gliomas are malignant primary brain tumors with poor prognosis. Recently, research was indicative of a tight connection between tumor malignancy and genetic alterations. Here, we propose an oncogenic implication of transforming acidic coiled-coil-containing protein 3 (TACC3) in gliomas. By comprehensively analyzing the Chinese glioma genome atlas (CGGA) and publicly available data, we demonstrated that TACC3 were overexpressed along with glioma grade and served as an independent negative prognostic biomarker for glioma patients. Functions’ annotations and gene sets’ enrichment analysis suggested that TACC3 may participate in cell cycle, DNA repair, epithelium-mesenchymal transition and other tumor-related biological processes and molecular pathways. Patients with high TACC3 expression showed CD133+ stem cell properties, glioma plasticity and shorter overall survival time under chemo-/radio-therapy. Additionally, a TACC3 associated the miRNA-mRNA network was constructed based on in silico prediction and expression pattern, which provide a foundation for further detection of TACC3-miRNA-mRNA axis function. Collectively, our observations identify TACC3 as an oncogene of tumor malignancy, as well as a prognostic and motoring biomarker for glioma patients.

The role of TACC3 in mitotic spindle organization

“…TACC1 and TACC2 are related to several human cancers, such as breast cancer (Fish et al, ; Yoshiaki et al, ) and gastric carcinoma (Lv et al, ), while TACC3 is associated with a number of cancers. TACC3 is highly expressed in most cancers tissues, such as prostate cancer (Li et al, ), glioma (Sun et al, ), cholangiocarcinoma (He et al, ), and colorectal cancer (Du et al, ), lung cancer (Jiang et al, ), gastric cancer (Yun et al, ). However, the expression of TACC3 is down‐regulated in thyroid cancer and ovarian carcinoma and preeclampsia (Peters et al, ; Ulisse et al, ; Zhu, Cao, Li, & Wang, ).…”

“…TACC1 and TACC2 are related to several human cancers, such as breast cancer (Fish et al, 2016;Yoshiaki et al, 2016) and gastric carcinoma (Lv et al, 2014), while TACC3 is associated with a number of cancers. TACC3 is highly expressed in most cancers tissues, such as prostate cancer , glioma (Sun et al, 2017), cholangiocarcinoma (He et al, Cytoskeleton. 2017;74:369-378. wileyonlinelibrary.com/journal/cm 2016), and colorectal cancer (Du et al, 2016), lung cancer (Jiang et al, 2016), gastric cancer (Yun et al, 2015).…”

TACC3 as an independent prognostic marker for solid tumors: a systematic review and meta-analysis

“…Then because of no usable data, 18 papers were excluded. As a result, a total of 11 studies were enrolled for the final analysis [ 10 , 14 – 23 ]. The main features of these eligible studies were displayed in Table 1 .…”

Proteomic Analysis of Combined Gemcitabine and Birinapant in Pancreatic Cancer Cells

“…TACC3 is an important spindle-regulatory protein in the centrosome-microtubule network during mitosis, and remained to be up-regulated after treatment of combination. Overexpression of TACC3 has been shown in a variety of human cancers, and correlated with lower survival rate and tumorigenesis ( Yun et al, 2015 ; Sun et al, 2017 ). Knockdown of TACC3 resulted in enhanced efficacy of other cytotoxic agents (e.g., paclitaxel) in preclinical models ( Yim et al, 2009 ).…”